Summit Therapeutics (SMMT) Reveals Phase II AK112 - 206 Trial Data
Summit Therapeutics (NASDAQ:SMMT) presented new Phase II AK112-206 data at ASCO, co-sponsored with Akeso, testing ivonescimab plus standard mFOLFOX6 in first-line metastatic colorectal cancer. The study reported a 70.8% objective response rate in treatment-naive U.S./China patients. Piper Sandler cut its price target to $16 (from $17) and kept Neutral.
How this was made
The 30-second read
Why it matters
New efficacy results at ASCO can re-rate the probability of success, but the stock’s after-hours weakness indicates the market is already comparing outcomes to Akeso’s HARMONi-6 and questioning repeatability in Summit’s HARMONi-3.
Market read
A concrete Phase II efficacy datapoint (70.8% ORR) is likely to attract biotech momentum flows, but the market’s immediate skepticism suggests traders will focus on PFS durability and cross-trial consistency.
What to watch
The article notes IDMC approval for proceeding and mentions investors focusing on whether effect size repeats; traders should watch for details on PFS timing, safety, and how ORR compares to historical bevacizumab+FOLFOX benchmarks.
Background
Summit’s ivonescimab (bispecific PD-1 and anti-angiogenesis) is being evaluated in colorectal cancer via the international Phase II AK112-206 trial, co-sponsored with Akeso.
Ticker impact
Summit presented new Phase II AK112-206 data for ivonescimab in first-line metastatic colorectal cancer, showing a 70.8% objective response rate.
Potentially volatile reaction: upside bias on efficacy, offset by uncertainty about durability/PFS and cross-trial repeatability.
The article cites a specific new efficacy datapoint (70.8% ORR) plus investor skepticism tied to HARMONi-3 vs HARMONi-6, implying both bullish and risk factors are active.
Market effects
Reinforces competitive intensity in bispecific oncology antibodies and the importance of cross-trial comparability (HARMONi-6 vs HARMONi-3).
None explicitly stated beyond U.S. and China cohorts in the trial.
International multisite data (U.S./China) may broaden perceived addressable market and investor confidence in global development.
Counterpoint
The headline ORR may not translate into durable benefit; investors may be discounting the lack of interim alpha and waiting for PFS maturity/IDMC-approved analyses.
Key entities
- companySummit Therapeutics
NASDAQ-listed developer of ivonescimab; presented AK112-206 Phase II data at ASCO.
- companyAkeso
Co-sponsor of the AK112-206 study; prior HARMONi-6 results are referenced as the benchmark.
- drugivonescimab
First-in-class bispecific antibody targeting PD-1 and anti-angiogenesis in a single molecule.
- clinical_trialAK112-206
International Phase II trial evaluating ivonescimab plus standard mFOLFOX6 in first-line metastatic colorectal cancer.
